Longdaysin

Research use only, not for human use.

Longdaysin is an inhibitor of CK1α and CK1δ (IC50s: 5.6/8.8 μM). It also can inhibit ERK2 (IC50: 52 μM).

Longdaysin is an inhibitor of CK1α and CK1δ (IC50s: 5.6/8.8 μM). It also can inhibit ERK2 (IC50: 52 μM).

Western Blot Analysis Cell Line:HEK293T cells Concentration:0-50 μM Incubation Time:24 h Result:Reduced the levels of phosphorylated LRP6, total LRP6, phosphorylated DVL2, activated β-catenin, and total β-catenin.

Animal Model:MDA-MB-231 xenografts Dosage:5 mg/kg Administration:i.p., every 3 days for 3 weeks Result:Decreased tumor cell density and proliferation (indicated by Ki-67).Reduced the expression of active and total β-catenin, and decreased the expression of phosphorylated and total LRP6, phosphorylated DVL2, and active and total β-catenin.Reduced mRNA expression of the Wnt target genes including Axin2, DKK1, LEF1, and Survivin.

——

Metabolic Enzyme/Protease

Casein Kinase

CKIα| CKIδ|CDK7|ERK2

——

——

1353867-91-0

335.33

C16H16F3N5

>98% (HPLC)

DMSO: 100 mg/mL (298.21 mM);Water: Insoluble

CC(C)n1cnc2c(NCc3cccc(c3)C(F)(F)F)ncnc12

9-Isopropyl-N-(3-(trifluoromethyl)benzyl)-9H-purin-6-amine

(-20℃)

With Ice Pack

≥ 2 years